II型RAF抑制剂托沃拉非尼在携带BRAF融合或NF1功能丧失突变的肿瘤模型中的临床前活性
Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation.
作者信息
Rastogi Shubhra, Perino Samantha, Lal-Nag Madhu, Wang Yujin, Blackman Samuel C, Venetsanakos Eleni
机构信息
Day One Biopharmaceuticals, Inc., Brisbane, California.
出版信息
Cancer Res Commun. 2025 Apr 1;5(4):668-679. doi: 10.1158/2767-9764.CRC-24-0451.
Abstract
Tovorafenib demonstrated efficacy in BRAF fusion but not in NF1-LOF mutant tumor models. Vertical pathway inhibition by combining type II RAF plus MEK inhibitors may have clinical relevance in NF1-LOF mutant tumors.
摘要
托法替尼在BRAF融合模型中显示出疗效，但在NF1基因功能缺失突变肿瘤模型中无效。联合使用II型RAF抑制剂和MEK抑制剂进行垂直通路抑制可能对NF1基因功能缺失突变肿瘤具有临床意义。
Zotero 插件